A Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC# 330507, IND# 57,966) in Combination With Docetaxel in Patients With Advanced Solid Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tanespimycin (Primary) ; Docetaxel
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions
- 17 Jun 2014 Biomarkers information updated
- 22 Dec 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.